Compare Stocks → the most reliable asset on earth is making a comeback (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALNANASDAQ:BCDANASDAQ:KRBPNASDAQ:LIFENASDAQ:ONVO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNAAllena Pharmaceuticals$0.07$0.06▼$1.17$37K1.1315.69 million shs96,558 shsBCDABioCardia$0.41-2.4%$0.44$0.36▼$2.92$10.55M1.5393,580 shs285,725 shsKRBPKiromic BioPharma$2.85+2.9%$2.29$0.16▼$8.97$3.68M1.999,387 shs5,627 shsLIFEaTyr Pharma$1.95-2.5%$1.80$1.08▼$2.70$132.11M1.25554,402 shs726,105 shsONVOOrganovo$1.03+2.0%$1.02$0.89▼$2.31$10.34M0.9125,123 shs43,794 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNAAllena Pharmaceuticals0.00%0.00%0.00%0.00%-66.67%BCDABioCardia-2.89%+1.75%-20.20%-38.72%-80.34%KRBPKiromic BioPharma+2.89%+1.64%-5.00%+227.59%-23.80%LIFEaTyr Pharma-2.50%-3.47%-2.50%+38.30%-7.58%ONVOOrganovo+1.98%0.00%+5.10%-7.21%-54.42%A lot of people are making this costly mistake (Ad)You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next oneMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALNAAllena PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABCDABioCardia1.5684 of 5 stars3.32.00.00.02.42.50.0KRBPKiromic BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ALIFEaTyr Pharma2.2386 of 5 stars3.43.00.00.03.81.70.0ONVOOrganovo0.8918 of 5 stars0.05.00.00.02.50.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNAAllena PharmaceuticalsN/AN/AN/AN/ABCDABioCardia2.50Moderate Buy$4.00882.80% UpsideKRBPKiromic BioPharmaN/AN/AN/AN/ALIFEaTyr Pharma2.75Moderate Buy$23.671,113.68% UpsideONVOOrganovoN/AN/AN/AN/ACurrent Analyst RatingsLatest ALNA, BCDA, ONVO, KRBP, and LIFE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/15/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/15/2024LIFEaTyr PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $16.002/21/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNAAllena PharmaceuticalsN/AN/AN/AN/A$0.23 per shareN/ABCDABioCardia$1.35M7.81N/AN/A$0.24 per share1.70KRBPKiromic BioPharmaN/AN/AN/AN/A($7.25) per shareN/ALIFEaTyr Pharma$350K377.46N/AN/A$1.54 per share1.27ONVOOrganovo$370K27.95N/AN/A$1.76 per share0.59Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNAAllena Pharmaceuticals-$48.66MN/A0.00N/AN/AN/A-287.46%-146.58%N/ABCDABioCardia-$11.91M-$0.62N/AN/AN/A-2,197.72%-645.14%-185.19%5/8/2024 (Estimated)KRBPKiromic BioPharma-$20.95M-$15.07N/A∞N/AN/AN/A-125.75%4/15/2024 (Estimated)LIFEaTyr Pharma-$50.39M-$0.96N/AN/AN/AN/A-49.84%-39.12%5/14/2024 (Estimated)ONVOOrganovo-$17.26M-$2.17N/AN/AN/A-4,061.12%-182.88%-138.52%7/11/2024 (Estimated)Latest ALNA, BCDA, ONVO, KRBP, and LIFE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023KRBPKiromic BioPharmaN/A-$4.16-$4.16-$4.16N/AN/A2/8/2024Q3 2024ONVOOrganovo-$0.41-$0.40+$0.01-$0.40$0.08 million$0.01 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALNAAllena PharmaceuticalsN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNAAllena PharmaceuticalsN/A1.581.58BCDABioCardiaN/A0.640.64KRBPKiromic BioPharmaN/A0.220.22LIFEaTyr Pharma0.026.276.27ONVOOrganovoN/A3.673.67OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNAAllena Pharmaceuticals7.33%BCDABioCardia20.57%KRBPKiromic BioPharma10.91%LIFEaTyr Pharma61.72%ONVOOrganovo8.23%Insider OwnershipCompanyInsider OwnershipALNAAllena Pharmaceuticals3.70%BCDABioCardia23.90%KRBPKiromic BioPharma3.25%LIFEaTyr Pharma3.14%ONVOOrganovo4.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALNAAllena Pharmaceuticals35122.08 million117.57 millionNot OptionableBCDABioCardia3025.91 million19.72 millionOptionableKRBPKiromic BioPharma311.29 million1.25 millionNot OptionableLIFEaTyr Pharma6567.75 million65.62 millionOptionableONVOOrganovo1510.04 million9.64 millionOptionableALNA, BCDA, ONVO, KRBP, and LIFE HeadlinesSourceHeadlineOrganovo (NASDAQ:ONVO) Receives New Coverage from Analysts at StockNews.comamericanbankingnews.com - March 25 at 2:16 AMHead-To-Head Comparison: TC Biopharm (NASDAQ:TCBP) & Organovo (NASDAQ:ONVO)americanbankingnews.com - March 25 at 1:36 AMOrganovo files patent for farnesoid x receptor agonist compound for treating diseasespharmaceutical-technology.com - March 24 at 6:42 PMOrganovo Holdings Stock (NASDAQ:ONVO) Earnings Dates and Earning Callsbenzinga.com - February 24 at 7:35 AMOrganovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - February 10 at 2:25 PMOrganovo Holdings Inc ONVOmorningstar.com - February 9 at 7:39 PMONVO Continues Progressfinance.yahoo.com - February 9 at 2:38 PMOrganovo: Fiscal Q3 Earnings Snapshotsfgate.com - February 8 at 7:40 PMOrganovo Holdings Unveils Corporate Presentation Onlinemsn.com - February 8 at 9:38 AMOrganovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congressfinance.yahoo.com - January 25 at 12:43 PMOrganovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congressfinance.yahoo.com - January 9 at 9:33 AMONVO Shares Experience Surge in Valueknoxdaily.com - January 4 at 10:15 AMChecking in on Organovo Holdings Inc (ONVO) after recent insiders movementknoxdaily.com - January 1 at 6:27 PMOrganovo Holdings: Unregistered Sales Of Equity Securities, Other Events, Financial Statements And Exhibitscbonds.com - December 30 at 8:48 AMOrganovo, Inc.: Organovo Provides Timing for Release of FXR314 Phase 2 NASH Resultsfinanznachrichten.de - December 7 at 8:37 AMOrganovo Provides Timing for Release of FXR314 Phase 2 NASH Resultsfinance.yahoo.com - December 6 at 9:16 AMOVNO Continues Developing Breakthrough Treatmentsmsn.com - November 13 at 4:20 PMCORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Planfinance.yahoo.com - November 13 at 8:43 AMOrganovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)finance.yahoo.com - November 11 at 9:02 AMOrganovo Highlights FXR314 Combination Therapy Potential and Planfinance.yahoo.com - November 8 at 12:13 PMONVO, FATH and BYU among mid-day moversmsn.com - November 7 at 3:44 PMONVO: A Company With Great Technology to Impact Health Carefinance.yahoo.com - October 10 at 12:56 PMOrganovo gets grant for patent granted for a three-dimensional biological intestinal tissue modelpharmaceutical-technology.com - September 28 at 7:53 PMOrganovo to Participate in the H.C. Wainwright Global Investment Conferencefinance.yahoo.com - September 8 at 4:06 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAllena PharmaceuticalsNASDAQ:ALNAAllena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.BioCardiaNASDAQ:BCDABioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.Kiromic BioPharmaNASDAQ:KRBPKiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.aTyr PharmaNASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.OrganovoNASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.